|
| |
Raptor PharmaceuticalRaptor Pharmaceutical Inc. is the culmination of years of experience and research by a consortium of scientists, investors, and creative minds with one common goal, the development of novel protein therapeutics directed at unmet medical needs. Raptor was incorporated in the State of Delaware on September 8, 2005. On January 27, 2006, Raptor purchased intellectual property pertaining to the research and development of receptor-associated protein (RAP) technologies from BioMarin Pharmaceutical Inc. This portfolio encompasses three pending patent applications and two provisional patent applications. For further details on our portfolio, please see the section on Intellectual Property.
| Contact Details: |
| 9 Commercial Blvd. Suite 200 |
| Novato |
| California |
| 94949-6118 |
| United States of America |
| Tel: | 1-415-382-8111 extension 200 |
| Fax: | 1-415-382-1368 |
| Email: | info@raptorpharma.com |
| WWW: | www.raptorpharma.com/
|
|
Loading...
|
Recent Publications by Raptor Pharmaceutical: |  |
Functional mimicry of the LDL receptor-associated protein through multimerization of a minimized third domain.
The LDL receptor-associated protein (RAP) is a ligand for the LDL... | 19th December, 2007
| Raptor Pharmaceutical Inc., 9 Commercial Boulevard, Suite 200, Novato, CA
| Biochem Biophys Res Commun. 2007 Dec 21;364(3):614-9. Epub 2007 Oct 18.
DOI Direct Link |
Minimization of the third domain of the LDL receptor-associated protein (RAP).
The third domain of the low-density lipoprotein receptor-associated... | 6th December, 2007
| Raptor Pharmaceutical Inc., 9 Commercial Boulevard, Suite 200, Novato, CA
| Biochem Biophys Res Commun. 2007 Sep 28;361(3):758-62. Epub 2007 Jul 26.
DOI Direct Link |
Press Releases on Raptor Pharmaceutical:
|
 |
| Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis |
23rd November, 2009 |
|
NOVATO, California, November 23 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP),
today announced results from a Phase 2b clinical trial of
|
| Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain |
23rd November, 2009 |
|
NOVATO, California, November 23 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP)
today announced the presentation of clinical trial data on
|
| Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum |
27th October, 2009 |
|
NOVATO, California, October 27 /PRNewswire/ -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that senior
management will present a corporate overview and update at the 8th Annual BIO
|
| Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH) |
12th October, 2009 |
|
NOVATO, California, October 12 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD),
announced positive findings from the completed treatment
|
| Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp. |
1st October, 2009 |
Merriman Curhan Ford Group, Inc. |
SAN FRANCISCO, Oct. 1 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as a financial advisor to TorreyPines Therapeutics, Inc. in the recent merger with Raptor
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 285 times since April 2007, the link to the organisation's website has been followed 44 times Search for more companies in Novato Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Raptor Pharmaceutical |
